PRX 002

Drug Profile

PRX 002

Alternative Names: NEOD-002; PRX-002; RG 7935

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Neotope Biosciences
  • Developer Prothena Corporation; Roche
  • Class Monoclonal antibodies
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 09 Nov 2016 Efficacy and adverse events data from a phase Ib trial in Parkinson's disease released by Prothena Biosciences
  • 09 Nov 2016 Prothena Biosciences and Roche plan a phase II trial for Parkinson's disease in 2017
  • 01 Sep 2016 Prothena Biosciences completes a phase I trial for Parkinson's disease in USA (NCT02157714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top